Expertise in
9
conditions

Dr. Timothy E. Ritter

Gastroenterology | Internal Medicine
505 S Nolan Dr, Ste A, 
Southlake, TX 
Expertise in
9
conditions
505 S Nolan Dr, Ste A, 
Southlake, TX 

Overview

Timothy Ritter is an Internal Medicine specialist and a Gastroenterologist in Southlake, Texas. Dr. Ritter is highly rated in 9 conditions, according to our data. His top areas of expertise are Ulcerative Colitis, Crohn's Disease, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Texas Southwestern Medical School - 1987|Parkland Health And Hospital System - 1993

Residency

Internal Medicine, Parkland Memorial Hospital - 1990

Specialties

Gastroenterology
Internal Medicine

Licenses

Internal Medicine in TX

Board Certifications

Gastroenterology- American Board Of Internal Med/Gastroenterology
- American Board Of Internal Med/Gastroenterology
Gastroenterology- American Board Of Internal Medicine

Fellowships

Gastroenterology, Parkland Memorial Hospital - 1993
GI, Parkland Health and Hospital System - 1993

Hospital Affiliations

Baylor Scott & White Medical Center - Grapevine

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Texas Digestive Disease Consultants
505 S Nolan Dr, Ste A, Southlake, TX 76092

Additional Areas of Focus

Dr. Ritter has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Biological
Study Drug: Nexvax2
Study Phase: Phase 2
View 6 Less Clinical Trials

44 Total Publications

Association of liver biomarker values beyond current thresholds and negative clinical outcomes in primary biliary cholangitis: analysis of a real-world healthcare claims database.
Association of liver biomarker values beyond current thresholds and negative clinical outcomes in primary biliary cholangitis: analysis of a real-world healthcare claims database.
Journal: Journal of comparative effectiveness research
Published: November 18, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Marlyn Mayo
Gastroenterology
Expertise in
23
conditions
Dr. Marlyn Mayo
Gastroenterology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (17.8 miles away)
214-645-8600
Languages Spoken:
English
See accepted insurances

Marlyn Mayo is a Gastroenterologist in Dallas, Texas. Dr. Mayo is highly rated in 23 conditions, according to our data. Her top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Cirrhosis, Autoimmune Hepatitis, and Liver Transplant.

Expertise in
20
conditions
Dr. Amit Singal
Gastroenterology
Expertise in
20
conditions
Dr. Amit Singal
Gastroenterology

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (17.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amit Singal is a Gastroenterologist in Dallas, Texas. Dr. Singal is highly rated in 20 conditions, according to our data. His top areas of expertise are Liver Cancer, Cirrhosis, Hepatitis C, Liver Transplant, and Colonoscopy.

Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology
Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology

Texas Digestive Disease Consultants

221 W Colorado Blvd PAV II,, Ste 630, 
Dallas, TX 
 (20.1 miles away)
214-941-6891
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Tarnasky is a Gastroenterologist in Dallas, Texas. Dr. Tarnasky is highly rated in 42 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Acute Pancreatitis, Pancreas Divisum, Endoscopy, and Gastric Bypass.

Frequently Asked Questions about Dr. Timothy E. Ritter

How do I make an appointment with Dr. Timothy E. Ritter?

You can book an appointment with Dr. Timothy E. Ritter by calling their office at 817-424-1525. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Timothy E. Ritter a top-rated expert for Ulcerative Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy E. Ritter is classified as an Elite expert for Ulcerative Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy E. Ritter specialize in?

While Dr. Timothy E. Ritter is a Gastroenterology, they have specific expertise in Ulcerative Colitis, Crohn's Disease, and Hemorrhagic Proctocolitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Timothy E. Ritter participate in research or clinical trials?

Yes. Dr. Timothy E. Ritter has published 44 articles and abstracts on conditions like Ulcerative Colitis. You can view a list of Dr. Timothy E. Ritter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy E. Ritter accept my insurance?

Dr. Timothy E. Ritter accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 817-424-1525 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritter's expertise for a condition
ConditionClose
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile